JP Morgan Chase’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,047,927
| Closed | -$35M | – | 7718 |
|
|
2026
Q1 | $35M | Buy |
2,047,927
+1,890,173
| +1,198% | +$40.7M | ﹤0.01% | 1631 |
|
|
2025
Q4 | $3.96M | Buy |
157,754
+104,238
| +195% | +$2.45M | ﹤0.01% | 3538 |
|
|
2025
Q3 | $1.21M | Sell |
53,516
-181,285
| -77% | -$4.23M | ﹤0.01% | 4449 |
|
|
2025
Q2 | $4.06M | Sell |
234,801
-188,999
| -45% | -$3.5M | ﹤0.01% | 3338 |
|
|
2025
Q1 | $9.27M | Buy |
423,800
+12,251
| +3% | +$338K | ﹤0.01% | 2614 |
|
|
2024
Q4 | $13.1M | Sell |
411,549
-3,473,181
| -89% | -$104M | ﹤0.01% | 2438 |
|
|
2024
Q3 | $112M | Buy |
3,884,730
+707,260
| +22% | +$26.2M | 0.01% | 899 |
|
|
2024
Q2 | $122M | Buy |
3,177,470
+963,161
| +43% | +$43.6M | 0.01% | 827 |
|
|
2024
Q1 | $130M | Sell |
2,214,309
-359,824
| -14% | -$22.9M | 0.01% | 818 |
|
|
2023
Q4 | $154M | Buy |
2,574,133
+356,386
| +16% | +$18.1M | 0.01% | 702 |
|
|
2023
Q3 | $84.4M | Buy |
2,217,747
+430,765
| +24% | +$18.9M | 0.01% | 878 |
|
|
2023
Q2 | $163M | Buy |
1,786,982
+138,530
| +8% | +$12M | 0.02% | 628 |
|
|
2023
Q1 | $109M | Sell |
1,648,452
-198,857
| -11% | -$11.5M | 0.01% | 757 |
|
|
2022
Q4 | $95.5M | Buy |
1,847,309
+907,262
| +97% | +$48.1M | 0.01% | 787 |
|
|
2022
Q3 | $64.2M | Sell |
940,047
-133,918
| -12% | -$7.92M | 0.01% | 927 |
|
|
2022
Q2 | $48.6M | Sell |
1,073,965
-192,273
| -15% | -$8.77M | 0.01% | 1051 |
|
|
2022
Q1 | $64.3M | Sell |
1,266,238
-321,640
| -20% | -$14.2M | 0.01% | 1043 |
|
|
2021
Q4 | $75.1M | Buy |
1,587,878
+54,736
| +4% | +$2.15M | 0.01% | 1009 |
|
|
2021
Q3 | $50.5M | Buy |
1,533,142
+1,118,049
| +269% | +$62.8M | 0.01% | 1171 |
|
|
2021
Q2 | $26.2M | Sell |
415,093
-21,187
| -5% | -$1.09M | ﹤0.01% | 1604 |
|
|
2021
Q1 | $18.7M | Sell |
436,280
-195,352
| -31% | -$9.24M | ﹤0.01% | 1812 |
|
|
2020
Q4 | $36.1M | Sell |
631,632
-71,773
| -10% | -$3.04M | 0.01% | 1244 |
|
|
2020
Q3 | $20.3M | Buy |
703,405
+602,266
| +595% | +$18M | ﹤0.01% | 1482 |
|
|
2020
Q2 | $3.3M | Buy |
101,139
+24,304
| +32% | +$781K | ﹤0.01% | 2765 |
|
|
2020
Q1 | $2.06M | Sell |
76,835
-350,211
| -82% | -$12.4M | ﹤0.01% | 2947 |
|
|
2019
Q4 | $13.1M | Buy |
427,046
+411,200
| +2,595% | +$11.4M | ﹤0.01% | 1899 |
|
|
2019
Q3 | $382K | Buy |
15,846
+2,570
| +19% | +$70.7K | ﹤0.01% | 4302 |
|
|
2019
Q2 | $325K | Buy |
13,276
+4,465
| +51% | +$90.8K | ﹤0.01% | 4434 |
|
|
2019
Q1 | $172K | Sell |
8,811
-414
| -4% | -$6.51K | ﹤0.01% | 4688 |
|
|
2018
Q4 | $122K | Buy |
9,225
+860
| +10% | +$13.2K | ﹤0.01% | 4772 |
|
|
2018
Q3 | $149K | Sell |
8,365
-47,376
| -85% | -$876K | ﹤0.01% | 4799 |
|
|
2018
Q2 | $1.23M | Buy |
55,741
+53,514
| +2,403% | +$1.23M | ﹤0.01% | 3706 |
|
|
2018
Q1 | $49K | Sell |
2,227
-108
| -5% | -$2.12K | ﹤0.01% | 4816 |
|
|
2017
Q4 | $51K | Buy |
+2,335
| New | +$34.4K | ﹤0.01% | 4888 |
|
Other funds holding APLS
JP Morgan Chase's APLS Position: Q2 2026 in Review
JP Morgan Chase sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,047,927 shares — an estimated $35M sold.
JP Morgan Chase first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $163M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- JP Morgan Chase reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 2,047,927 Apellis Pharmaceuticals shares in Q2 2026, an estimated $35M.
- JP Morgan Chase first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
- JP Morgan Chase's Apellis Pharmaceuticals position peaked at $163M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.